Dozens of noted scientists, philanthropists, and university, state and local leaders gathered Jan. 18 to celebrate the dedication of one of the world’s largest neuroscience research buildings, a gleaming state-of-the-art facility on the Washington University Medical Campus. They toured its sophisticated, newly christened labs; listened intently as Washington University scientists described the lifesaving work they […]
Tag: Albert Kim
Kim named inaugural Danforth WashU Physician-Scientist Scholar
Albert H. Kim, MD, PhD, a professor of neurological surgery at Washington University School of Medicine in St. Louis, has been named the inaugural William H. Danforth Washington University Physician Scholar. He is the first researcher named as part of the School of Medicine’s new Physician-Scientist Investigators Initiative, which aims to recruit and retain elite […]
New Brain Tumor Center at Siteman Cancer Center to be Part of Neuroscience Research Building
When a patient is informed of a brain tumor, the experience is frightening. “When anyone finds out they have a brain tumor. It is super scary,” described neurosurgeon and scientist Dr. Albert Kim, MD, PhD, the inaugural director of the new Brain Tumor Center at Siteman Cancer Center at Barnes Jewish Hospital and Washington University […]
Brain Tumor Center established at Siteman Cancer Center
Washington University School of Medicine in St. Louis and Barnes-Jewish Hospital have established the Brain Tumor Center, a multidisciplinary practice of physicians and scientists whose mission is to provide leading-edge, patient-centric care for brain tumor patients while also developing transformative basic, translational and clinical research to develop new therapies and improve patient outcomes. Neurosurgeon and scientist Albert H. Kim, […]
Aggressive brain tumor mapped in genetic, molecular detail
Glioblastoma is among the most aggressive and devastating of cancers. While rare compared with other cancers, it’s the most common type of brain cancer. Even with intensive therapy, relatively few patients survive longer than two years after diagnosis, and fewer than 10% of patients survive beyond five years. Despite extensive studies focused on genomic features […]